Work

Supplementary Figure 4 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Year: 2025

Type: supplementary-materials

Abstract: Supplementary Figure 4 shows no observable adverse safety in animals after treatment with REG/bsAb.

DOI: 10.1158/1535-7163.29760638

Authors: Izuchukwu F. Okpalanwaka, Elizabeth A. Daugherity, Amanda L. McCormick, Trevor S. Anderson, Savanna L. Smith, Caryn Lawrence, Duke Appiah, Devin B. Lowe

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4412843674

Cites:

Cited by:

Related to: 10